| In vitro–in vivo correlations: general concepts, methodologies and regulatory applications I González-García, V Mangas-Sanjuán, M Merino-Sanjuán, M Bermejo Drug development and industrial pharmacy 41 (12), 1935-1947, 2015 | 41 | 2015 |
| Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers D Oltra-Noguera, V Mangas-Sanjuan, A Centelles-Sangüesa, ... Journal of Pharmacological and Toxicological Methods 71, 21-32, 2015 | 40 | 2015 |
| Safety and clinical activity of MEDI1873, a novel GITR agonist, in advanced solid tumors AS Balmanoukian, JR Infante, R Aljumaily, A Naing, AV Chintakuntlawar, ... Clinical Cancer Research 26 (23), 6196-6203, 2020 | 38 | 2020 |
| A systems pharmacology model for inflammatory bowel disease V Balbas-Martinez, L Ruiz-Cerdá, I Irurzun-Arana, I Gonzalez-Garcia, ... PLoS One 13 (3), e0192949, 2018 | 36 | 2018 |
| Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach ML Ruiz-Cerdá, I Irurzun-Arana, I González-Garcia, C Hu, H Zhou, ... European Journal of Pharmaceutical Sciences 94, 46-58, 2016 | 21 | 2016 |
| IVIVC approach based on carbamazepine bioequivalence studies combination I González-García, V Mangas-Sanjuan, M Merino-Sanjuán, ... Die Pharmazie-An International Journal of Pharmaceutical Sciences 72 (8 …, 2017 | 13 | 2017 |
| Population pharmacokinetic model of lithium and drug compliance assessment I Pérez-Castelló, V Mangas-Sanjuan, I González-García, ... European Neuropsychopharmacology 26 (12), 1868-1876, 2016 | 11 | 2016 |
| A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development A Ruiz-Garcia, P Baverel, D Bottino, M Dolton, Y Feng, I González-García, ... Journal of Pharmacokinetics and Pharmacodynamics 50 (3), 147-172, 2023 | 10 | 2023 |
| Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma R Arends, X Guo, PG Baverel, I González-García, J Xie, N Morsli, ... Oncoimmunology 10 (1), 1898104, 2021 | 10 | 2021 |
| Two-step in vitro-in vivo correlations: Deconvolution and convolution methods, which one gives the best predictability? Comparison with one-step approach B Sánchez-Dengra, I González-García, M González-Álvarez, ... European Journal of Pharmaceutics and Biopharmaceutics 158, 185-197, 2021 | 8 | 2021 |
| Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy I González‐García, V Pierre, VFS Dubois, N Morsli, S Spencer, ... CPT: Pharmacometrics & Systems Pharmacology 10 (3), 230-240, 2021 | 6 | 2021 |
| Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation I González-García, A García-Arieta, M Merino-Sanjuan, ... European Journal of Pharmaceutical Sciences 119, 200-207, 2018 | 4 | 2018 |
| Imputing Biomarker Status from RWE Datasets—A Comparative Study C Traynor, T Sahota, H Tomkinson, I Gonzalez-Garcia, N Evans, ... Journal of Personalized Medicine 11 (12), 1356, 2021 | 2 | 2021 |
| Pharmacokinetic-pharmacodynamic modelling of systemic IL13 blockade by monoclonal antibody therapy: a free assay disguised as total J Hood, I González-García, N White, L Marshall, VFS Dubois, P Vicini, ... Pharmaceutics 13 (4), 519, 2021 | 2 | 2021 |
| Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer. V Pierre, X Guo, I Gonzalez-Garcia, N Morsli, AJ Yovine, W Li, R Narwal, ... Journal of Clinical Oncology 38 (15_suppl), 6549-6549, 2020 | 2 | 2020 |
| Systems Pharmacology model for Inflammatory Bowel Disease (IBD) V Balbas-Martinez, L Ruiz-Cerdá, I Irurzun-Arana, I González-García, ... International Conference on Systems Biology, 2016 | 2 | 2016 |
| Towards a Survival Risk Prediction Model for Metastatic NSCLC Patients on Durvalumab Using Whole-Lung CT Radiomics KA Patwardhan, H RaviPrakash, N Nikolaou, I Gonzalez-Garcia, ... bioRxiv, 2024.02. 01.578458, 2024 | | 2024 |
| EARLY PREDICTIONS OF RESPONSE AND SURVIVAL FROM A TUMOR GROWTH INHIBITION (TGI) MODEL IN HEAD AND NECK SQUAMOUS-CELL CARCINOMA (HNSCC) PATIENTS TREATED WITH DURVALUMAB. I Gonzalez-Garcia, V Pierre, V Dubois, N Morsli, S Spencer, P Baverel, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S119-S120, 2020 | | 2020 |
| Validación de procedimientos poblacionales mediante convolución para el establecimiento de corelaciones in vitro-in vivo IG Garcia Universitat de València, 2018 | | 2018 |
| Building an inflammatory bowel disease network, a systems pharmacology approach I Gonzalez-Garcia, I Irurzun-Arana, L Ruiz-Cerda, C Hu, H Zhou, ... 6th American conference on Pharmacometrics (ACoP-6) 42 (suppl. 1), S83-S84, 2015 | | 2015 |
